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Abstract
Liver X receptors limit cellular lipid uptake by stimulating the transcription of Inducible Degrader 
of the LDL Receptor (IDOL), an E3 ubiquitin ligase that targets lipoprotein receptors for 
degradation. The function of IDOL in systemic metabolism is incompletely understood. Here we 
show that loss of IDOL in mice protects against the development of diet-induced obesity and 
metabolic dysfunction by altering food intake and thermogenesis. Unexpectedly, analysis of tissue-
specific knockout mice revealed that IDOL affects energy balance, not through its actions in 
peripheral metabolic tissues (liver, adipose, endothelium, intestine, skeletal muscle), but by 
controlling lipoprotein receptor abundance in neurons. Single-cell RNA sequencing of the 
hypothalamus demonstrated that IDOL deletion altered gene expression linked to control of 
metabolism. Finally, we identify VLDLR rather than LDLR as the primary mediator of IDOL 
effects on energy balance. These studies identify a role for the neuronal IDOL-VLDLR pathway in 
metabolic homeostasis and diet-induced obesity.
Introduction
Lipoprotein receptors are key determinants of cardiovascular disease due to their pivotal 
roles in regulating blood cholesterol levels. Dissecting the function and regulation of 
members of the LDL receptor (LDLR) superfamily has advanced our understanding of 
fundamental processes such as receptor-mediated endocytosis1, neuronal development2, and 
lipid-responsive transcription3. Cells maintain optimal cholesterol levels in part by 
regulating the uptake of cholesterol from circulating lipoproteins via the LDL receptor. 
Sterol regulatory element binding proteins (SREBPs) are transcription factors activated by 
low cholesterol levels that stimulate the expression of genes that drive cholesterol synthesis 
and uptake, including LDLR. Conversely, when cells accumulate excess cholesterol, 
activation of the Liver X Receptors (LXRs) promotes the expression of genes that restore 
homeostasis by increasing cholesterol efflux and transport4,5. Both the LXR and SREBP 
pathways also exert negative feedback on each other6,7.
One LXR-mediated feedback mechanism is to limit the influx of lipoprotein cholesterol into 
cells via the Inducible Degrader of the LDL Receptor (IDOL), an E3 ubiquitin ligase that 
targets members of the LDLR family for degradation8,9. Previous work elucidated the 
molecular mechanisms underlying IDOL-dependent degradation of its lipoprotein receptor 
targets9–13, and addressed its role in the species-specific regulation of hepatic cholesterol 
metabolism14–18. IDOL and its targets are expressed in a number of metabolically-active 
tissues other than liver, but the physiological role of IDOL in systemic lipid metabolism 
remains poorly understood. Furthermore, the lipoprotein receptor(s) through which IDOL 
regulates metabolism are unknown.
Here we report that mice globally deficient in IDOL expression are protected against diet-
induced obesity and metabolic dysfunction. Unexpectedly, loss of IDOL in individual 
metabolic tissues, including liver, skeletal muscle, adipose and intestine, failed to 
recapitulate the phenotype of the whole-body knockouts, prompting us to search for an 
alternative mechanism. Ultimately, we traced this metabolic phenotype to loss of IDOL in 
the central nervous system, and to the consequent dysregulation of VLDLR protein levels. 
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Deletion of IDOL from mouse neurons phenocopies the whole-body IDOL knockout mice. 
Our data identify the IDOL-VLDLR axis in neurons as a regulatory pathway impacting 
systemic energy balance.
Results
Global IDOL-knockout mice are protected from diet-induced metabolic dysfunction
Previous efforts to characterize the physiological role of IDOL have focused primarily on its 
ability to regulate cholesterol metabolism. Unexpectedly, in the course of these studies we 
noted that 18-month old chow-fed IDOL-KO mice (developed at UCLA) demonstrated that 
deletion of IDOL protected against age-induced obesity, even when the mice were fed 
standard chow diet (Extended Data Fig. 1A, 1B). We then proceeded to challenge mice with 
obesogenic diets. Group-housed IDOL-deficient knockout mice fed a western diet (WD) 
enriched in fat and cholesterol for 15 weeks were 22% lighter than WT controls (Fig. 1A). 
Body composition analysis by MRI revealed that IDOL-KO mice were leaner, averaging 
11% body fat compared to 32% in the WT mice (Fig. 1B). This was accompanied by 
reduced hepatic lipid accumulation and smaller adipocytes in the inguinal white adipose 
tissue depot (Fig. 1C). As the gene encoding IDOL is an LXR target, we postulated that the 
differential response to diet may require dietary cholesterol to stimulate LXR activity; 
however, the IDOL-KO mice were also leaner when fed a high-fat diet (HFD) that contained 
comparatively little cholesterol (Extended Data Fig. 1C).
We also analyzed a second, independently-derived IDOL knockout mouse line generated by 
crossing Idol-floxed mice developed at AstraZeneca, denoted IDOL(AZ), with a Rosa26-Cre 
transgenic line, denoted CreR26 (Supplemental Fig. 1). When maintained on low-fat low-
cholesterol diet (LFD), these CreR26/IDOL(AZ) mice also showed a lean phenotype after 
20-weeks of age (Extended Data Fig. 1D). The phenotype was exaggerated when the mice 
were challenged with a high-fat high-cholesterol diet (HFHC; Extended Data Fig. 1E).
We found no evidence of a generalized developmental growth defect in either strain of 
IDOL-knockout mice. There were no differences in lean body mass (Extended Data Fig. 
1F), nasal to anal length (Extended Data Fig. 1G), or to body temperature attributable to 
genotype (Extended Data Fig. 1H). The reduced adiposity in the WD-fed IDOL-KO mice 
was associated with improved glucose clearance (Fig. 1D; nine weeks of diet) and insulin 
tolerance (Fig. 1E; fourteen weeks of diet). Although we did not detect differences in food 
intake in short term studies, analysis of mice housed singly over the course of weeks (WT, 
n=14; IDOL KO, n=12) revealed reduced food intake in the genetic absence of IDOL (Fig 
1F), associated with reduced diet-induced adipose expansion (Fig 1G, 1H).
Deletion of IDOL from peripheral metabolic tissues does not protect from obesity
We hypothesized that the metabolic phenotype of IDOL-deficient mice resulted from 
primary actions of the IDOL pathway in one or more metabolic tissues. To test this idea, we 
crossed Idol-floxed mice to a range of tissue-specific Cre transgenic lines to generate tissue-
selective IDOL knockouts. We first analyzed the contribution of the liver to the IDOL-KO 
phenotype using Alb-Cre-IDOL(AZ)-floxed mice (Idol(AZ)f/f; CreAlb) generated at 
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AstraZeneca. Hepatic deletion of IDOL had no effect on the obesity of mice challenged with 
the obesogenic HFHC diet (Fig. 2A, 2F), nor on glucose metabolism (Extended Data Fig 
2A, 2B), suggesting that the liver is not the primary driver of the global IDOL-KO 
phenotype.
Given the reduced adiposity in IDOL-KO mice, we next considered that a direct effect of the 
IDOL pathway on adipose tissue might explain the phenotype. We crossed AdipoQ-Cre 
transgenics19 to Idolf/f mice to generate mice lacking IDOL expression in both white and 
brown fat (Idolf/f; CreAdipoQ). We challenged the mice with 15 weeks of western-diet 
feeding but saw no effect on mass or adiposity (Fig. 2B, 2G) or on glucose or insulin 
tolerance (Extended Data Fig. 2C, 2D). In a complimentary approach, we developed a 
transgenic mouse expressing a dominant active form of human IDOL under the control of 
Fabp4 promoter (aP2-Tg). This line showed nearly complete ablation of VLDLR protein 
levels in both white and brown adipose depots, confirming the activation of the IDOL 
pathway (Extended Data Fig. 3A, 3B). Despite this change in VLDLR levels, we observed 
no differences in mass between the aP2-IDOL Tg mice and their littermate controls fed WD 
for twelve weeks (Extended Data Fig. 3C). Accordingly, neither adiposity nor responses to 
glucose and insulin challenges were affected by the transgene (Extended Data Fig. 3D–3F). 
Collectively the data collected from both gain- and loss-of-function mice lead us to conclude 
that adipose-intrinsic actions of IDOL cannot explain the phenotype of global IDOL-
knockout mice.
We next considered the possibility that IDOL-dependent changes in LDLR or VLDLR 
protein levels may be acting in the vasculature to alter lipid delivery and metabolism in 
adipocytes secondarily. This would be consistent with studies showing that VLDLR affects 
lipoprotein lipase activity20–23. We crossed Idolf/f mice with a line expressing Cre from the 
Cadherin 5 promoter (commonly referred to as VE Cadherin-Cre)24 to generate an 
endothelial-specific IDOL knockout line (Idolf/f; CreCdh5). Loss of IDOL activity in the 
endothelium had no effect on the initiation or progression of obesity after challenge with 
WD for 15 weeks (Fig. 2C, 2H). There was also no difference in glucose or insulin tolerance 
between groups (Extended Data Fig. 2E, 2F).
An alternative possibility was that altered caloric intake from the diet could be causing the 
change in weight gain. Idol is highly expressed in the intestine8, and it is plausible that 
altering lipoprotein receptor expression could affect dietary lipid absorption or efflux. We 
crossed the Idol-floxed mice with Villin-Cre transgenics to generate intestine-specific 
knockout mice (Idolf/f; CreVil). However, loss of IDOL activity in the intestine did not affect 
mass gain or adiposity (Fig. 2D, 2I) and did not affect glucose or insulin tolerance (Extended 
Data Fig. 2G, 2H). Prompted by the high level of expression of Vldlr in muscle, we also 
generate muscle-specific IDOL-knockouts (Idolf/f; CreMck) by crossing the IDOL floxed 
mice to MCK-Cre transgenics25. Again, the tissue-selective knockout failed to recapitulate 
the effects of whole-body IDOL loss (Fig. 2E, 2J and Extended Data Fig. 2I, 2J).
IDOL regulates systemic energy balance through the VLDL receptor
IDOL controls the abundance of three proteins (LDLR, VLDLR, and ApoER2) via 
ubiquitination, which targets the proteins for lysosomal degradation9,13. We therefore 
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hypothesized that the metabolic phenotype of the global IDOL knockout was due to changes 
in levels of one or more of these lipoprotein receptors. To test this idea, we developed two 
double-knockout (DKO) mouse lines in which IDOL and either LDLR or VLDLR were 
deleted simultaneously. We did not pursue an ApoER2 compound mutant line as global 
ApoER2 knockout mice are sterile26, have severe neurological defects at baseline2, and 
floxed-Apoer2 mice are not available. We challenged cohorts of single and double IDOL-
knockout mice with HFHC diet. Consistent with the result of prior cohorts, the mass (Fig. 
3A and 3B) and adiposity (Fig. 3E and 3F) of global IDOL-KO mice diverged rapidly from 
the WT group, reaching statistical significance after two to four weeks on diet (p<0.05 by 
repeat measures two-way ANOVA). Throughout the study, the IDOL KO and IDOL-LDLR 
DKO groups were indistinguishable with respect to body mass and adiposity (Fig. 3A, 3E). 
LDLR is the only IDOL target expressed in the liver, further supporting the conclusion that 
the liver is not the primary driver of the global IDOL-KO phenotype.
Whole body deletion of VLDLR has previously been shown to be protective against diet-
induced obesity22,27,28. To further understand the contributions of IDOL to body weight we 
compared the responses of WT, VLDLR-KO, IDOL-KO, and IDOL-VLDLR DKO mice to 
HFHC diet feeding (Fig. 3B, 3F). The VLDLR single knockout mice and IDOL-VLDLR 
DKO showed comparable protection against adipose expansion upon high-fat diet feeding, 
confirming previous reports that deletion of VLDLR is protective against diet-induced 
obesity. They further show that deletion of IDOL, which leads to an over-abundance of 
VLDLR protein (Extended Data Fig. 4A, 4B), has an even more pronounced protective 
effect on WT mice, but has no additional effect on the background of VLDLR deficiency. 
These data strongly suggest that altered abundance of the VLDLR receptor and not the 
LDLR is an important contributor to systemic energy balance.
We assessed metabolic fitness in the compound mutant mice by performing a glucose 
tolerance test after six weeks on HFHC diet (Fig. 3C) and an insulin tolerance test after ten 
weeks on diet (Fig. 3D). Both the IDOL-KO and IDOL-LDLR DKO groups had improved 
glucose clearance and enhanced response to a bolus of insulin relative to the WT group; 
however, the IDOL-VLDLR DKO group was indistinguishable from the WT group. These 
data were analyzed by comparing the AUCs using a one-way ANOVA (Fig. 3G, 3H). 
Collectively, these data provide strong evidence for the hypothesis that regulation of VLDLR 
protein levels is important for the maintenance of metabolic homeostasis.
Acute knockdown of IDOL in the central nervous system increases energy expenditure
VLDLR is most highly expressed in the brain, muscle, fat, and the endothelium. Having 
ruled out the peripheral metabolic tissues as the source of the IDOL-VLDLR effect on 
energy balance, we considered the CNS as a potential site of action. Prior studies showed 
that the IDOL pathway in the CNS affects the function of both microglia and neurons29,30; 
however, the possibility that central actions of IDOL affect metabolism has not been 
addressed. To test whether IDOL was acting centrally, we developed a CNS-optimized 
antisense oligonucleotide (ASO) targeting Idol. Dose-response studies determined that 40 μg 
given by intracerebroventricular injection was the minimum dose required for maximal 
suppression of Idol expression in whole brain homogenates collected two weeks after the 
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injection (Extended Data Fig. 5A). Using this optimized protocol, we knocked down Idol 
expression in 5-week old C57Bl/6J mice and initiated a western diet-induced obesity study 
one-week post-injection. At the end of the seven-week western diet study, Idol expression 
was suppressed by 65% in the hypothalamus of ASO-injected mice relative to vehicle-
treated control mice (Fig. 4A). As expected, Idol knockdown in the CNS was associated 
with increased VLDLR protein in the hypothalamus (Fig. 4C). The mice treated with the 
IDOL ASO weighed less than their control counterparts after six weeks on diet (Fig. 4B; 
p<0.01 by repeat measures two-way ANOVA). These findings were confirmed in a second 
cohort of mice using a CNS-optimized negative control ASO (Extended Data Fig. 5B). 
Consistent with the whole-body knockout, the Idol ASO-treated mice were leaner by MRI 
analysis (Fig. 4D) and had smaller fat pads upon dissection (Extended Data Fig. 5C, 5D).
Although IDOL ASO-treated mice phenocopied the whole-body IDOL KO mice, we did not 
observe changes to food intake. We hypothesized that the body weight difference may 
involve changes in energy expenditure. We performed indirect calorimetry (Oxy-Max 
CLAMS, Columbus Instruments) on the cohorts after 2–3 weeks on diet (before their body 
mass and adiposity diverged; Extended Data Fig. 5E). The ASO-treated mice exhibited 
increased energy expenditure (Fig. 4F), determined with two different data analysis 
methods: 1. the NIDDK Mouse Metabolic Phenotyping Centers energy expenditure analysis 
page (http://www.mmpc.org/shared/regression.aspx) and 2. the BWH-Harvard web 
application for indirect calorimetry analysis (https://calrapp.org)31. The treatment effect was 
significant (p<0.05 by ANCOVA) when either the overall mean total body mass or the mean 
lean body mass of each treatment group was used as the covariate. The increased energy 
expenditure could not be explained by changes in locomotor activity (Fig. 4G, 4H).
Livers of the IDOL ASO-treated mice had less lipid deposition, similar to the global IDOL 
KO mice (Extended Data Fig. 5F). The Idol-knockdown mice also had smaller white adipose 
tissue depots containing smaller adipocytes, but we did not find an obvious increase in 
multi-locular cells resembling beige adipocytes (Fig. 4E). Histological analysis of brown 
adipose tissue revealed smaller cells with more abundant lipid droplets (Fig. 4E), consistent 
with increased energy expenditure. Increased BAT activity is associated with alterations in 
glucose catabolism32 while acute pharmacological stimulation of BAT can reduce 
circulating lipids by driving fatty acid oxidation33. The ASO-treated mice appeared to have 
increased carbohydrate metabolism, but we did not observe a consistent change in fat 
oxidation (Extended Data Fig. 5G, 5H). ASO treatment increased phosphorylation of 
hormone sensitive lipase in the subcutaneous white adipose depot (Fig. 4I), a canonical 
downstream target of adrenergic receptor mediated PKA stimulation32; and we noted 
increased abundance of tyrosine hydroxylase in the BAT (Fig. 4J), consistent with increased 
catecholamine production by sympathetic nerves. These observations linked acute 
knockdown of Idol in the central nervous system to systemic changes in energy expenditure; 
however, they did not provide insight into the brain cell type(s) responsible for the 
phenotype.
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IDOL deletion alters hypothalamic gene expression linked to energy balance
The increased energy expenditure seen when CNS expression of Idol was knocked down 
suggests that IDOL regulates one or more energy homeostasis circuits in the brain. We 
employed Drop-seq, a single cell RNA-sequencing technique, to obtain an overview of the 
changes in the transcriptional landscape of individual cell populations in the hypothalamus 
provoked by IDOL deletion (Fig. 5A). We placed wild-type and IDOL-KO mice on HFHC 
for two weeks and then analyzed hypothalamic gene expression. Clustering algorithms 
successfully identified twenty-six populations of cells in the hypothalamus, including eleven 
non-neuronal populations and fifteen distinct populations of neurons (Fig. 5B and Extended 
Data Fig. 6A–C). We analyzed the dataset for Vldlr gene expression and found two clusters 
with significant numbers of cells with high Vldlr expression: oligodendrocytes and neurons 
(Extended Data Fig 6D). When the genotype of the neurons was unmasked, the clustering 
analysis revealed several populations of neurons that had incompletely overlapping clusters 
of wild-type and IDOL knockout cells (Fig. 5C). Such separations indicate altered global 
transcriptional profiles in these populations. We interrogated two populations of cells that 
have been extensively studied for their contributions to energy homeostasis: AGRP and 
POMC neurons34,35. A third population of cells, histaminergic neurons expressing Slc18a2, 
was also profiled because of its apparent reduction in the IDOL knockout mice; however, 
our analysis of transcriptional changes did not reveal any reason for the difference in this 
population. It is likely that the observed changes in cell abundance are an artifact of it being 
a relatively under-represented cluster even in the wild-type mice.
Analysis of transcript abundance in the AGRP neurons revealed that loss of IDOL altered 
the expression of a battery of genes linked to energy balance. Each of the labeled genes in 
each of the volcano plot of Fig. 5D are annotated in GWAS, OMIM or PubMed as being 
associated with energy homeostasis (Supplemental Data Table 2). The differentially 
expressed genes identified in AGRP neurons showed an enrichment of these genes (Fig. 5D). 
More modest differences were observed between genotypes in POMC and histaminergic 
neurons (Extended Data Fig. 6E, F). Interestingly, two key orexigenic genes expressed were 
downregulated in the AGRP neurons of IDOL-KO mice: the genes encoding agouti-related 
peptide and neuropeptide Y (Fig. 5E). AGRP neurons have also been associated with the 
negative regulation of energy expenditure36–38. Collectively, these data reveal that deletion 
of IDOL in the CNS altered the transcriptional regulation of several key neural circuits 
known to regulate energy balance.
IDOL deletion in neurons regulates energy balance
We followed up on the ASO and single cell RNA-sequencing results by creating pan-neuron 
conditional knockout mice by crossing the Idolf/f mice with SynI-Cre transgenics (Idolf/f; 
CreSynI). Similar to the global-KO mice, the CreSynIIdolf/f mice had reduced mass and 
adiposity when challenged with the western diet (Fig. 6A, 6B; n=18). Again, we conducted 
long-term food intake measurements to maximize our ability to detect small changes in food 
intake. As shown in Fig. 6C, the CreSynIIdolf/f mice consumed less food per week than their 
Idolf/f littermates. This finding shows that the changes in food intake in IDOL-deficient mice 
are the result of primary IDOL effects in neurons. We assessed energy expenditure by 
indirect calorimetry but did not detect any statistically significant differences between the 
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two groups. Western blot analysis of subcutaneous white adipose tissue showed enhanced 
phosphorylation of HSL in CreSynIIdolf/f mice (Fig. 6D). The activation of HSL clearly 
indicates that deletion of IDOL from neurons affected peripheral energy homeostasis, 
however if changes in whole-body energy expenditure were present they were too subtle for 
the calorimeter to detect.
To distinguish the relative contributions of reduced food intake and increased energy 
expenditure to the IDOL-KO phenotype, we endeavored to minimize the energy expenditure 
effects by housing the mice at thermoneutrality (30 °C for 12 weeks). Relative to WT mice, 
global IDOL-KO mice gained less mass and adiposity on the obesogenic HFHC diet, 
suggesting that changes in food intake were sufficient to affect body weight in the absence 
of energy expenditure differences (Fig. 6E, 6F).
We endeavored to identify a specific hypothalamic locus driving the IDOL KO phenotype; 
however, viral-Cre-mediated deletion of IDOL in neurons in the arcuate nucleus (ARC), 
ventromedial hypothalamus (VMH), or the paraventricular nucleus of the hypothalamus 
(PVH) was not sufficient to recapitulate the CreSynIIdolf/f mouse phenotype (Extended Data 
Fig. 7). While the results of our viral experiments did not allow us to identify a precise 
neuron population responsible for the IDOL KO phenotype, our work with the SynI-Cre 
mice clearly demonstrated that deletion of IDOL from neurons protected mice against diet-
induced obesity by reducing food intake while enhancing energy expenditure pathways. 
They further identify IDOL-mediated regulation of neuronal VLDL receptor as a previously 
unrecognized modulator of whole-body energy homeostasis.
Discussion
The ability of an organism to adapt to changing nutritional availability is fundamental to its 
survival. A plurality of mechanisms maintaining whole-body energy homeostasis have been 
selected for over the course of mammalian evolution. In this study, we identify the IDOL-
VLDLR pathway in neurons as a previously unknown modulator of whole-body energy 
homeostasis. Two independent lines of global IDOL-KO mice (one derived at UCLA and 
one at AstraZeneca) exhibited a highly reproducible phenotype of resistance to diet-induced 
obesity. Despite the abundant expression of IDOL and its targets in adipose tissue, tissue-
specific studies pointed to the CNS as the primary site of IDOL action in the regulation of 
energy balance. Loss of VLDLR but not LDLR expression on an IDOL-KO background 
abolished the protective effects of IDOL deficiency on the development of obesity.
Previous studies have established the molecular mechanisms by which IDOL regulates the 
abundance of its lipoprotein receptor targets. IDOL forms a homodimer which recognizes a 
specific conserved amino acid sequence in its membrane-bound targets for recognition and 
ubiquitin transfer. To date only three proteins have been identified that meet this stringent 
criterion: the LDL receptor and its two most closely-related family members, VLDL 
receptor and ApoER2. Although unexpected, our finding that VLDLR expression is required 
for the effects of IDOL on whole body metabolism is consistent with prior work 
demonstrating that VLDLR is important to metabolic homeostasis. One of the initial 
observations made by Herz and colleagues when they developed the VLDLR-KO mice was 
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that the mice exhibited a reduction in mass and BMI relative to WT controls on a mixed 
background27. These findings were confirmed by other groups22,28 and we replicated this 
finding again here (Fig. 3). Prior mechanistic analyses have suggested that VLDLR in the 
periphery acts in the endothelium to enhance lipoprotein lipase-dependent hydrolysis of 
triglycerides20–23. It is important to point out, however, that the consequence of IDOL 
deficiency is increased, rather than decreased, VLDLR protein levels. Coupled with prior 
work, our results suggest that the appropriate balance of VLDLR protein levels in the CNS 
is important for the maintenance of whole-body energy homeostasis.
While this study was under review, Van Loon et al.39 described a similar phenotype of 
obesity resistance in the UCLA-generated IDOL knockout mouse line that we had 
previously provided them. These authors attributed the body weight differences in global 
IDOL-KO mice to IDOL activity in the liver, based on correlations between hepatic Idol 
expression and metabolic parameters in a BXD dataset. By contrast, our data do not support 
a causal role for hepatic IDOL in the phenotype. We tested the role of IDOL in the liver 
directly with hepatocyte-specific conditional IDOL-KO mice (Albumin-Cre; Fig. 2) and 
found that loss of liver IDOL did not confer protection against diet-induced metabolic 
dysfunction. Furthermore, the only lipoprotein receptor target of IDOL that is expressed by 
the liver is the LDL receptor, which we unequivocally demonstrated was not required for 
IDOL’s effects on the response to high-fat diet (Fig. 3A, 3B). Nevertheless, we conclude that 
the phenotype of the UCLA global IDOL KO mice is consistent between different vivarium 
conditions.
Although energy balance is maintained by multiple brain regions40,41, the role of the 
hypothalamus is particularly prominent34,42. Acting via the sympathetic nervous 
system32,43,44. the hypothalamus is a key effector of CNS influence on adipose tissue, 
including response to cold. It has also been implicated in the metabolic actions of 
Leptin36,45, FGF2146, PPARɣ agonists47,48, and thyroid hormone49,50. We observed 
increased VLDLR protein levels in hypothalamus of both the IDOL-KO mice and IDOL-
ASO-treated mice, suggesting that this region likely contributes to IDOL’s metabolic effects. 
Furthermore, our single cell RNA-seq study demonstrated that deletion of IDOL altered the 
transcriptional landscape in several populations of neurons with well-established roles in the 
regulation of energy balance.
We investigated the potential for IDOL to regulate central control of metabolism using a 
combination of acute and chronic interventions, each of which provided insight into the 
physiological role of IDOL. The acute nature of the ASO studies allowed us to detect 
increased energy expenditure at a whole-organism level, linking IDOL in the CNS to 
peripheral energy homeostasis. We did not detect changes to food intake during a two week-
long evaluation, perhaps due to differences between chronic deletion of IDOL compared 
with acute knockdown, or due to the duration of the food intake study.
Based on the Vldlr expression pattern seen in our single cell RNA-sequencing data, we 
focused our attention on IDOL in neurons. The complete loss of IDOL from neurons 
provided evidence that IDOL regulates food intake, consistent with the reduced expression 
of Agrp and Npy seen in our single cell RNA-sequencing data of whole-body IDOL 
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knockout mice. The relative importance of altered food intake to the phenotype was 
confirmed by thermoneutrality studies showing that body weight differences persisted when 
the role of thermogenesis was minimized. Unfortunately, we have not yet been able to 
identify specific hypothalamic regions involved in the effects of IDOL on energy balance. 
We acknowledge that the viral-Cre approach used here suffers from the inherent weakness 
that the SynI promoter-driven Cre will be expressed in all infected neurons, which might 
might the role of specific neuronal populations51. Individual populations of neurons within a 
given hypothalamic nucleus may have opposing effects, as with POMC and AGRP neurons 
in the arcuate nucleus52.
Collectively, our studies identify the IDOL-VLDLR pathway as a previously unrecognized 
mode of regulating whole-body energy homeostasis. We expect that this observation will 
prompt further investigation into the specific cellular mechanism(s) by which cell-surface 
VLDLR levels regulate energy balance. The CNS contains a specific set of lipoproteins. 
Both ApoE and ApoJ (also called Clusterin)–two apolipoproteins found in cerebrospinal 
fluid–are known ligands for VLDLR26,53,54. Several non-apolipoprotein ligands have also 
been proposed for VLDLR, including Reelin2 and F-spondin55. While there is evidence that 
ApoJ can bind and modulate Leptin response in cell culture56, to date none of these ligands 
have conclusively been shown to regulate whole body energy homeostasis. In the periphery, 
VLDLR has a clear role facilitating lipolytic activity of LPL20,22, and thereby enhancing the 
production of free fatty acids. Free fatty acid sensing by the hypothalamus is a well-
established modulator of neuronal activity57, affecting peripheral metabolism58–60, but the 
role of central VLDLR in this process has not been explored. Future studies will be required 
to define precisely how IDOL activity in the brain conveys a VLDLR-dependent signal to 
the periphery to regulate energy balance and which specific neuronal populations are 
involved.
Methods
Contact for Reagent and Resource Sharing:
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the lead contact, Dr. Peter Tontonoz (PTontonoz@mednet.ucla.edu).
The antisense oligonucleotides were provided by IONIS Pharmaceuticals and are subject to 
an MTA between Ionis Pharmaceuticals and the University of California, Los Angeles.
Experimental Models:
The UCLA line of IDOL-KO mice was generated with a gene trap cassette inserted in intron 
1, which could be released with FRT recombination to create conditional knockout mice in 
which exon 2 was “floxed”61. All UCLA mice were studied after ten backcrosses to 
C57Bl/6J.
The AstraZeneca line of IDOL KO mice was bred to a pure C57Bl/6N strain such that exon 
2 was flanked by loxP sites. Whole body IDOL KO mice were derived from this strain by 
crossing the Idolf/f mice with Rosa26 Cre transgenic mice. This strain was also used to 
create hepatocyte-specific Idol−/− mice by crossing with Albumin Cre transgenic mice62.
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The aP2-IDOL transgenic mice were generated at the UCLA core facility. We cloned a 
dominant active form of human IDOL (K293R, K309R, K310R, K320R) into a pBluescript 
vector containing the 5.4kb Fabp4 enhancer/promoter (A gift from Ronald Kahn) followed 
by bovine growth hormone polyA. The linearized construct was gel purified and 
microinjected into C57Bl/6J mice fertilized zygotes. Founders were identified using the 
following PCR primers (Fwd- GCCAGGAGGGCTCTGTACA; Rev-
GAATAGAATGACACCTACTCAGACAAT). The mouse studies conducted at UCLA were 
reviewed and approved by the Chancellor’s Animal Research Committee. The mouse 
studied conducted by AstraZeneca were approved by Gothenburg Ethics Committee for 
Experimental Animals, license nr: 38–2011.
Mouse studies:
All studies performed with male mice in climate-controlled facilities maintained on a 12h 
light/dark cycle constant temperature of 22°C with group housed mice, unless otherwise 
noted. Pilot studies used both genders of mice; however, female mice are resistant to diet-
induced obesity and required prolonged challenges with more severe diets to elicit adiposity 
changes. Consequently, male mice were used for all subsequent studies. LFD and HFHC 
studies with the AstraZeneca mouse lines: Dietary challenge was initiated in 8-week-old 
littermate mice. Body weights were recorded on a weekly basis. Body length (nose to base 
of the tail) was assessed at 4, and 20 weeks of age. Food intake in AZ mice was measured at 
15-weeks of age by fasting mice for 12h during the dark period before single-housing them 
in cages (23 × 16cm) with pre-weighed aliquots of food for 48h. Body composition was 
assessed in 20-week-old animals by dual energy X-ray absorptiometry (DEXA, GE Lunar, 
Madison, USA) in isoflurane anaesthetized mice. Metabolic fitness was determined by oral 
glucose tolerance tests (2g/kg) performed at 22 weeks of age. The energy content of the 
feces was determined using a bomb calorimeter (C 5000, IKA Werke GmbH & Co. KG, 
Germany). Preliminary WD and HFD studies (Fig. 1 and Extended Data Fig. 1): we placed 
5–6-week old littermate mice on test diets for 15 weeks and measured body mass weekly. 
We separated the mice to measure food intake at week 12 before returning them to group 
housing. Metabolic fitness was determined by administering an intraperitoneal glucose 
tolerance test (1g/kg) at week 9, and an intraperitoneal insulin tolerance test (1U/kg) at week 
14. We measured body composition by MRI after 15 weeks on western diet (EchoMRI 3-
in-1, Houston, TX, USA) Western diet-fed conditional knockout studies: we placed 5–6-
week littermate mice on diet for 15 weeks and measured their body mass weekly. We 
measured adiposity by MRI at baseline, then every four weeks until study termination. 
Metabolic fitness was determined with an intraperitoneal glucose tolerance test (1g/kg) at 6-
weeks and an intraperitoneal insulin tolerance test (1U/kg) at 10-weeks.
HFHC diet fed single and double knockout studies: we placed male 7–8-week-old mice on 
the HFHC diet and measured mass, adiposity, and metabolic fitness as described for the 
western diet conditional knockout studies above. Each cohort in the double knockout studies 
was arranged to maximize the number of littermate controls. Double knockout mice had 
single knockout littermate controls, while single knockouts had wild-type littermate 
controls).
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Western diet ASO study: We performed a pilot dose-response study in five-week-old male 
C57Bl/6J mice to determine the minimum dose of ASO given by intracerebroventricular 
injection required for the maximal suppression of Idol expression in whole brain 
homogenates relative to vehicle control-treated mice (Extended Data Figure 5A). For the 
adiposity studies, five-week-old male C57Bl/6J mice ordered from The Jackson Laboratory 
were administered 40μg ASO or 10μL vehicle control by intracerebroventricular injection. 
The study was repeated using 40μg IDOL-targeting ASO or 40μg control ASO. The mice 
recovered for one week before we initiated the dietary challenge. We measured energy 
expenditure by indirect calorimetry after 2–3 weeks of western diet feeding (Columbus 
Instruments Oxymax CLAMS, Columbus, OH, USA). We measured adiposity by MRI at 
baseline, immediately prior to the calorimetry experiments, at 4 weeks on diet at 7 weeks on 
diet just prior to study termination. Mice were singly housed from the time they were moved 
to the metabolic chambers until the end of the study. We monitored food intake from week 4 
to 7.
Food Intake studies: Littermate mice were singly-housed in standard housing and fed 
Western Diet ad libitum. The mass of diet administered and consumed was recorded weekly.
Thermoneutrality studies: Littermate mice were group housed in monitored climate-
controlled facilities maintained on a 12h light/dark cycle constant temperature of 30°C.
Virogenetic studies: Ten-week-old littermate UCLA-derived Idolf/f male mice were 
anaesthetized with isofluorane and received analgesics (0.01mg/mL buprenorphine, 
0.58mg/mL carprofen) pre- and post- surgery. The AAV-hSyn-GFP or AAV-hSyn-GFP-Cre 
(UNC Vector Core, titer ≥ 6×1012 vg/mL) was injected bilaterally into the following brain 
regions with the listed coordinates and volumes: Arcuate Nucleus (ARC): A-P: −1.57 mm 
from Bregma; lateral: ±0.2 mm from Bregma; D-V: 5.8 mm from the cortex, 125nL/side; 
Paraventricular nucleus of the Hypothalamus (PVH): A-P: −.33 mm from Bregma; lateral: 
±0.25 mm from Bregma; D-V: 4.4 mm from the cortex, 250nL/side; Ventromedial 
Hypothalamus (VMH): A-P: −1.6 mm from Bregma; lateral: ±0.45 mm from Bregma; D-V: 
5.4 mm from the cortex, 200nL/side. Mice were allowed to recover for 1 week before 
starting them on western diet for one week before we measured energy expenditure using the 
OxyMax CLAMS system. Upon completion of the energy expenditure study, the mice were 
singly-housed and food intake was measured as described above.
Study termination (all cohorts): mice were fasted for 6 hours beginning at 8:00am, then 
euthanized by isoflurane overdose, exsanguinated by cardiac puncture before cervical 
dislocation. Blood was collected in EDTA-coated tubes and centrifuged at 2000g for 15min 
to separate plasma. Tissues were collected from the mice and either snap frozen in liquid 
nitrogen or fixed in 4% paraformaldehyde.
Antisense oligonucleotide production:
Antisense oligonucleotides (ASOs) targeting IDOL (5’-TTCCTTTTTTCCACACGCCA-3’) 
were provided by Ionis Pharmaceuticals, Carlsbad CA. Complete ASO chemistry 
information is as follows. IDOL ASO (Tes Tes mCes mCeo Tes Tds Tds Tds Tds Tds mCds 
mCds Ads mCds Ads mCeo Ges mCes mCes Ae) and control ASO (mCes mCeo Teo Aeo 
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Tes Ads Gds Gds Ads mCds Tds Ads Tds mCds mCds Aeo Geo Geo Aes Ae) where capital 
letters indicate base abbreviation, m=5-methylcytosine, e=2’-O-methoxyethylribose (MOE), 
k= (S)-2’,4’-constrained 2’-O-ethyl (cEt), d=deoxyribose, s=phosphorothioate, and 
o=phosphodiester63–65.
Gene expression:
Differences in gene expression were determined by real-time RT-qPCR (Diagenode, 
Denville, NJ, USA) from RNA isolated from frozen tissues with TRIzol (Life Technologies, 
Carlsbad, CA, USA) according the manufacturer’s instructions.
Western blot analysis:
Proteins were isolated from frozen tissue using a Dounce homogenizer on ice with RIPA 
buffer (Boston Bioproducts, Ashland, MA, USA) containing phosphatase and protease 
inhibitors (Roche, Mannheim, Germany). Equal masses of proteins were separated by 
electrophoresis through Bis-Tris gels before being transferred to PVDF membrane. The 
membranes were probed using the antibodies listed in the key resources table.
Histology:
Tissues were fixed in 4% paraformaldehyde and stored in ethanol before being mounted in 
paraffin. 10μm sections were cut and stained by hematoxylin and eosin by the UCLA 
Translational Pathology Core.
Single Cell RNA Sequencing
Single cell preparation:
Single cell suspensions were generated at a final concentration of 100 cells/μl in 0.01% 
BSA-PBS by digesting freshly dissected hypothalamus tissue with papain (Worthington, 
Lakewood, NJ, USA). Briefly, the hypothalamus was rapidly dissected then transferred into 
4 mL ice-cold Hibernate A (HA, BrainBits LLC, Springfield, IL, USA) / B27 (Invitrogen, 
Carlsbad, CA, USA)/Glutamax Fisher Scientific, Hampton, NH, USA) (HABG) and 
incubated in a water bath at 30°C for 8 min66,67. The supernatant was discarded, and the 
remaining tissue was incubated with papain (12 mg in 6 ml HA-Ca) at 30 °C for 30 min. 
After incubation, the papain solution was removed from the tissue and washed with HABG 
three times. Using a siliconized 9-in Pasteur pipette with a fire-polished tip, the suspension 
was triturated approximately ten times in 45 sec. Next, the cell suspension was carefully 
applied to the top of the prepared OptiPrep density gradient (Sigma Aldrich, St. Louis, MO, 
USA). The gradient was then centrifuged at 800g for 15 min at 22 °C. We aspirated the top 6 
ml containing cellular debris. To dilute the gradient material, we mixed the desired cell 
fractions with 5 ml HABG. The cell suspension containing the desired cell fractions was 
centrifuged for 3 min at 22°C at 200g, and the supernatant containing the debris was 
discarded. Finally, the cell pellet was loosened by flicking the tube and the cells were re-
suspended in 1 ml 0.01% BSA (in PBS). This final cell suspension solution was passed 
through a 40-micron strainer (Fisher Scientific, Hampton, NH, USA) to discard debris, 
followed by cell counting.
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Drop-seq single cell barcoding, library preparation and sequencing:
Drop-seq was performed using standard methodology68, with the following modifications: 
1). The number of beads in a single PCR tube was increased to 4,000/tube. 2). The number 
of PCR cycles was increased to 4+11 cycles. 3). Multiple PCR tubes were pooled prior to 
size selection and purification with AMPure XP (Beckman Coulter, Brea, CA). The libraries 
were then checked on a TapeStation (Agilent, Santa Clara, CA, USA) for library quality, 
average size, and concentration estimation. The samples were then tagmented using the 
Nextera DNA Library Preparation kit (Illumina, San Diego, CA, USA) and multiplex indices 
were added. The Drop-seq library molar concentration was quantified by Qubit Fluorometric 
Quantitation (ThermoFisher, Canoga Park, CA, USA) and library fragment length was 
estimated using a TapeStation. Sequencing was performed on an Illumina HiSeq 4000 
(Illumina, San Diego, CA, USA) instrument using the Drop-seq custom read 1B primer 
(IDT, Coralville, IA, USA). 100bp paired end reads were generated with an 8bp index read 
for multiplexing. Read 1 consists of the 12bp cell barcode, followed by the 8bp UMI. Read 2 
contains the single cell transcripts.
Drop-seq data pre-processing and quality control:
The demultiplexed fastq files from the Drop-seq sequencing data were processed into a 
digital gene expression matrix using the dropSeqPipe (https://github.com/Hoohm/
dropSeqPipe) SnakeMake wrapper for Drop-seq tools version 1.13. Briefly, read pairs with 
quality score less than 10 were discarded, transcript reads were trimmed to remove TSO 
contamination and polyA tails and then aligned to mm10 using STAR v2.5.0c with default 
settings. A digital gene expression (DGE) matrix for each sample was generated where each 
row is the read count of a gene and each column a unique single cell. The transcript counts 
of each cell were normalized by the total number of UMIs for that cell. These values were 
then multiplied by 10,000 and Ln transformed. Digital gene expression matrices from the six 
samples (3 WT and 3 KO samples) were combined to create a pooled digital gene expression 
matrix. Single cells were identified from background noise by using a threshold of at least 
250 genes and 500 transcripts, resulting in a dataset of 6600 cells from IDOL knock out 
samples and 4800 cells from wild type samples.
Identification of cell clusters:
The Seurat R package (version 2.3.1; https://github.com/satijalab/seurat) was used to project 
all sequenced cells onto two dimensions using t-Distributed Stochastic Neighbor Embedding 
(tSNE) and shared nearest neighbor graph-based clustering69 was used to define clusters. To 
further refine the neuronal cell clusters, clusters expressing neuronal-specific markers were 
pooled and re-analyzed separately in a similar fashion, only considering this neuronal 
subset. Briefly, the most highly variable genes were identified using the mean and dispersion 
(variance/mean) which were used to scale and center the data. Principal Components 
Analysis (PCA) was performed on this normalized data and significant PCs were identified 
using the JackStraw permutation-based approach70. These significant PCs were used in 
tSNE to project the data onto two dimensions and the graph-based clustering to identify cell 
clusters.
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Resolving cell identities of the cell clusters:
To resolve the identities of the cell clusters, known cell-type specific markers from previous 
studies were curated and checked for expression patterns within the cell clusters. A cluster 
showing high expression levels of a known marker gene specific for a particular cell type 
was considered to carry the identity of that cell type. Known markers for major 
hypothalamus cell types and neuronal subtypes were retrieved from Romanov71, Chen et al.
72
, and Campbell et al.73. These markers were sufficient to define all major cell types as well 
as neuronal subpopulations.
Identification of differentially expressed genes between WT and KO:
Within each identified cell type, single cells from WT and KO samples were compared for 
differential gene expression using a Wilcoxon Rank Sum Test. To be considered in the 
analysis, the gene had to be expressed in at least 25% of the single cells from one of the two 
groups within that cell type and there had to be at least a 0.25 log fold change in gene 
expression between the groups.
Data quantification and statistical analysis:
All data except the Energy Expenditure data were analyzed using GraphPad Prism v7 with a 
predetermined alpha value of 0.05. The values reported in the text and figures are the group 
means ± SEM where the n-number refers to the number of animals per group. The data were 
analyzed for the assumptions of parametric statistical methods (equal variance and normal 
distribution) and log-transformed if required. If the log-transformed data did not meet the 
assumptions of parametric statistical methods, the non-transformed data were analyzed using 
a non-parametric method, including the Mann Whitney test and the Wilcoxon rank sum test, 
as indicated in the appropriate figure legend. Parametric comparisons between two groups 
were done by t-test and of multiple groups with a single independent factor by one-way 
ANOVA. If a parameter was measured over time, then data were analyzed by repeat 
measures two-way ANOVA where time is one independent factor. The glucose- and insulin-
tolerance tests were analyzed by calculating the area under the curve (AUC) for each mouse 
and then analyzing the AUC data set by t-test or one-way ANOVA, as appropriate.
The energy expenditure data generated by the indirect calorimetry experiment were analyzed 
using two methods: 1. the NIDDK Mouse Metabolic Phenotyping Centers using their energy 
expenditure analysis page (http://www.mmpc.org/shared/regression.aspx) and 2. the R 
programming language with CalR, a custom package for analysis of indirect calorimetry 
using analysis of covariance with a graphical user interface (https://calr.bwh.harvard.edu)31.
Data Availability: The data that support the findings of this study are available from the 
corresponding author upon request, furthermore the Reporting Summary is available from 
the Nature Metabolism website. We deposited the single-cell RNA sequencing data in the 
NCBI Gene Expression Omnibus - accession number GSE119960.
Extended Data
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Extended Data Figure 1. Metabolic phenotype of IDOL-deficient mice.
(a,b) 18-month-old IDOL KO mice are protected against age-induced adiposity. (a) Mean 
mass and standard error of the mean; n=9 WT, n=10 KO mice, ***p<0.001, ****p<0.0001 
vs. WT by two-tailed t-test. (b) Mean body fat percentage +/− the standard error of the 
mean; n=9 WT, n=10 KO mice, ***p<0.001, ****p<0.0001 vs. WT 2-tailed t-test. (c) 
Growth curve for littermate male mice fed a 60% kcal high fat diet (HFD) starting when the 
mice were 6 weeks old. The mean values are shown +/− the standard error of the mean; n=5 
WT and n=6 KO mice *p<0.05 by repeat measures ANOVA. (d) Growth curve for littermate 
male IDOL(AZ)f/f mice with or without whole-body Rosa26 Cre fed a low-fat diet from 8 
weeks of age. The mean mass is shown +/− SEM; n=10 mice per group. (e) Growth curve 
for littermate male IDOL(AZ)f/f mice with or without whole-body Rosa26 Cre fed a high fat 
high cholesterol diet from 8-weeks of age; n=8 Idol(AZ)f/f mice n=9 CreR26+Idol(AZ)f/f 
mice; *p<0.05 by repeat measures ANOVA (f) Unchanged lean body mass in male IDOL 
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knockout mice administered test diets despite adiposity changes measured by MRI. Mean 
lean mass is shown +/− SEM; n=9 WT and n=10 KO mice fed Chow, n=5 WT and n=7 mice 
fed western diet, n=5 WT and n=6 KO mice fed the 60% HFD, p-values calculated by two-
way ANOVA with Sidak post hoc tests. (g) Body length measured from nose to anus at 20 
weeks of age for male mice fed either a low-fat diet (LFD) or a high-fat high-cholesterol diet 
(HFHC) for 12 weeks. The mean values are shown +/− the standard error of the mean. Low-
fat diet: n=10 mice per genotype. High Fat High Cholesterol diet: n=8 Idol(AZ)f/f mice and 
n=9 CreR26+Idol(AZ)f/f mice. P-values calculated by repeat measures ANOVA. (h) Mean 
body temperature +/− SEM measured rectally in response to fasting in mice fed a high-fat 
high-cholesterol diet; n=8 WT and n=9 IDOL KO mice. The precise n-number, p-value, and 
details of all statistical testing are provided in the source data file.
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Extended Data Figure 2: Glucose and insulin tolerance tests conducted on Idolf/f and conditional 
knockouts with tissue-specific deletion of IDOL.
(a-b) Mean blood glucose levels +/− SEM for liver-specific conditional IDOL KO mice 
challenged with an oral glucose tolerance test (2g/kg) at 22 weeks of age fed either (a) the 
low-fat diet; n=12 mice per genotype or (b) the high-fat high-cholesterol diet for 16 weeks; 
n=11 mice per genotype. (c-j) Mean blood glucose levels +/− SEM for male mice fed a 
western diet challenged with an intraperitoneal glucose tolerance test (1 g/kg, shown on the 
left) after six weeks on diet and an intraperitoneal insulin tolerance test (1 U/kg, shown on 
the right) after ten weeks on diet. (c,d) Adipose-specific conditional IDOL KO; n=11 Idolf/f, 
n=9 CreAdipoQIdolf/f mice. (e,f) Endothelium-specific conditional IDOL KO; n=13 Idolf/f, 
n=10 CreCdh5Idolf/f mice. (g,h) Intestine-specific conditional IDOL KO; n=8 Idolf/f, n=4 
CreVilIdolf/f mice. (i,j) Muscle-specific conditional IDOL KO; n=10 mice per genotype for 
the GTT and n=10 Idolf/f, n=9 CreMckIdolf/f mice for the ITT.
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Extended Data Figure 3: Adipose-specific transgenic IDOL mice are not protected from diet-
induced obesity.
(A) Ablation of VLDLR protein levels in the subcutaneous inguinal white adipose tissue of 
the aP2-IDOL transgenic mice. This blot is representative of many independent experiments 
conducted by two independent researchers. (B) Reduced VLDLR protein in the interscapular 
brown adipose tissue of the aP2-IDOL transgenic mice. This blot is representative of many 
independent experiments conducted by two independent researchers. (c) Growth curve for 
WT and aP2-IDOL transgenic mice fed a western diet from 5 weeks of age showing the 
mean mass +/− SEM; n=13 WT and n=9 aP2-IDOL transgenic mice (d) Mean body fat 
percentage measured by MRI +/− SEM for n=13 WT and n-9 aP2-IDOL transgenic mice 
after 12 weeks of western diet feeding. (e) Intraperitoneal glucose tolerance test (1g/kg) 
administered after six weeks of western diet feeding; n=13 WT and n-9 aP2-IDOL 
transgenic mice. (f) Intraperitoneal insulin tolerance test (1U/kg) administered after ten 
weeks of western diet feeding n=13 WT and n-9 aP2-IDOL transgenic mice.
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Extended Data Figure 4: IDOL regulates systemic energy balance through the VLDL receptor.
100ug of RIPA isolate from the hypothalamus of individual wild-type (WT), Idol−/− (KO), 
Idol−/−Ldlr−/− (LDLR DKO), or Idol−/−Vldlr−/− (VLDLR DKO) mice was loaded per lane of 
a Tris-Acetate NuPAGE gel. The image is representative of many independent experiments. 
These samples were repeated twice to assess reproducibility. (a) Western blot analysis of 
VLDLR protein levels in the hypothalamus at study termination. (b) Western blot analysis of 
LDLR protein levels in the hypothalamus at study termination.
Lee et al. Page 20
Nat Metab. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data Figure 5: Acute knockdown of Idol in the central nervous system increases 
energy expenditure.
(a) Optimization of the dose of ASO required to suppress Idol expression in whole-brain 
homogenates measured 8-weeks post-injection. The values represent the mean expression of 
Idol in a whole brain homogenate 8-weeks post-injection +/− SEM; n=4 mice per time point. 
(b) Growth curve for male mice placed on western diet one week after 
intracerebroventricular injection of Idol-targeting antisense oligonucleotide (IDOL ASO) or 
CNS-optimized control (CTRL ASO). The mean masses are shown +/− SEM; *p<0.05, 
**p<0.01, ***p<0.001 by repeat measures two-way ANOVA, n=10 mice treated with CTRL 
and n=5 mice treated with IDOL ASO. The (c) Macroscopic view of interscapular brown 
adipose tissue depots after seven weeks on western diet. These images are representative of 
the ten mice per group in the ASO study. (d) Macroscopic view of subcutaneous (inguinal) 
white adipose tissue depots after seven weeks on western diet. These samples are 
representative of the ten mice per group in the ASO study. (e) No statistically significant 
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differences in body composition at the onset of CLAMS experiment. The mean total body 
mass, lean body mass, and fat body mass are shown +/− SEM; statistical significance 
determined by two-way ANOVA to account for multiple testing, n=10 mice per group. The 
precise n-number, p-value, and details of all statistical testing are provided in the source data 
file file. (f) Reduced lipid accumulation in the livers of ASO treated mice evident with 
hematoxylin and eosin staining of 5μm sections of liver (10x objective). These images are 
representative of three mice per treatment group that were analyzed for histology. (g) 
Calculation of carbohydrate metabolism in the n=10 mice per group. The mean energy 
expenditure derived from carbohydrate metabolism is shown +/− SEM for each time point. 
(h) Calculation of lipid oxidation in the n=10 mice per group. The mean energy expenditure 
derived from lipid metabolism is shown +/− SEM for each time point.
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Extended Data Figure 6: Single cell RNA sequencing examination of the transcriptional 
landscape of the hypothalamus with Drop-seq.
Clustering analysis combined with expression profiling of a panel of marker genes allowed 
us to discriminate 26 unique clusters of cells in the hypothalamus. (a) Violin plots 
demonstrate the expression patterns of the 38 marker genes used to identify the cell clusters. 
Individual data points indicating the magnitude of gene expression in a single cell are 
superimposed on a probability density plot for the distribution of the data; the expression 
analysis is based on the data collected from n=11,453 single cells. (b) Global gene 
expression relationships in the 11,453 single cells isolated from the hypothalamic tissues of 
six mice projected onto two dimensions using t-distributed Stochastic Neighbor Embedding 
(tSNE). The clusters were defined using shared nearest neighbor graph-based clustering. (c) 
tSNE plot of the neuronal cells identified in the Drop-seq experiment (n=3369 single cells). 
(d) Violin plot demonstrating that Vldlr is only appreciably expressed in neuron and 
oligodendrocyte cell populations. Individual data points indicating the magnitude of gene 
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expression in a single cell; the expression analysis is based on the unique molecular 
identities (UMI) data collected from n=11,453 single cells. (e-f) Volcano plots of the 
differentially expressed genes analyzed by two-sided Wilcoxon rank sum tests in (e) POMC+ 
(n=24 WT and n=26 Idol−/− cells) and (f) Histaminergic neurons (n=23 WT and n=11 Idol−/
− neurons. Labeled genes are linked to whole body metabolic homeostasis – see 
Supplemental Data Table 2 for details.
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Extended Data Figure 7: Neuron-specific virogenetic deletion of IDOL from individual 
hypothalamic nuclei is insufficient to protect against diet-induced obesity.
(a-c) Adeno-associated virus (AAV) expressing either GFP-Cre or GFP regulated by the 
Synapsin I (SynI) promoter were injected into the arcuate nucleus (ARC: panels a-c) or the 
paraventricular nucleus of the hypothalamus (PVH: panels d-f). (a-c) Deletion of IDOL 
from neurons in the ARC had no effect on body mass or food intake for mice fed a western 
diet for 12 weeks; n=8 mice injected with AAV-expressing GFP (GFPARC-SynI), n=8 mice 
injected with AAV expressing Cre-GFP (CreARC-SynI). (a) An image of the ARC showing 
GFP-positive cells to demonstrate successful infection of neurons; the image is 
representative of the sixteen mice injected in the ARC study. (b) Growth curve showing the 
mean mass of the mice from each treatment group +/− one standard deviation. (c) The mean 
cumulative mass of food consumed per mouse +/− one standard deviation. (d-f) Deletion of 
IDOL from neurons in the PVH had no effect on body mass or food intake for mice fed a 
western diet for 12 weeks; n=8 mice injected with AAV expressing GFP (GFPPVH-SynI), n=9 
mice injected with AAV expressing Cre-GFP (CrePVH-SynI). (d) An image of the PVH 
showing GFP-positive cells to demonstrate successful infection of neurons; the image is 
representative of the seventeen mice injected in the PVH experiment. (e) Growth curve 
showing the mean mass of the mice from each treatment group +/− one standard deviation. 
(f) The mean cumulative mass of food consumed per mouse +/− one standard deviation.
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Figure 1: Global IDOL knockout mice are protected from diet-induced metabolic dysfunction.
(a) Growth curve for wild-type (WT) vs. Idol knockout (KO) mice fed western diet from 5–6 
weeks of age. The mean masses are shown +/− the standard error of the mean (SEM); n=12 
WT, n=9 KO mice *p<0.05 by repeat measures two-way ANOVA. (b) Adiposity reported as 
body fat percentage +/− the SEM measured by MRI after 15 weeks of western diet feeding; 
n=5 WT, n=7 KO mice ****p<0.0001 by 2-tailed t-test. (c) H&E-stained sections of liver 
and epididymal white adipose tissue (eWAT) depots from mice maintained on western diet 
for 15 weeks; these images are representative of tissues analyzed from both the UCLA-
produced and AstraZeneca-produced lines. (d) Intraperitoneal glucose tolerance test (1 
mg/kg) administered after 9 weeks of western diet feeding. The mean blood glucose levels 
are shown +/− the SEM; n=10 WT, n=9 KO mice *p<0.05 by 2-tailed t-test of the area under 
the curve (AUC) (e) Intraperitoneal insulin tolerance test (1 U/kg) administered after 14 
weeks of western diet feeding. The mean blood glucose levels are shown +/− SEM; n=7 WT, 
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n=6 KO mice *p<0.05 by 2-tailed t-test of the area under the curve (AUC). (f-h) Single-
housed IDOL KO mice consume less food than WT littermates, protecting them from diet-
induced adipose expansion; n=14 WT, n=12 KO mice **p<0.01, ****p<0.0001 WT vs. KO 
by repeat measures ANOVA. (f) The mean food consumed per mouse is labeled +/− SEM. 
(g) The mean mass gained per mouse after being placed in single housing +/− SEM. (h) 
Adiposity reported as body fat percentage +/− the SEM measured by MRI. The precise n-
number, p-value, and details of the statistical testing are provided in the source data file.
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Figure 2: Deletion of IDOL from peripheral tissues does not protect against diet-induced 
metabolic dysfunction.
(a-e) Growth curves showing the mean mass +/− SEM for male mice from each conditional 
knockout mouse strain tested. (f-j) Adiposity reported as body fat percentage +/− SEM 
measured by MRI or DEXA after 15 weeks consuming the indicated test diet. (a, f) Liver-
specific IDOL KO mice (n=12 Idol(AZ)f/f, n=12 Idol(AZ)f/f CreAlb) fed a high-fat, high-
cholesterol (HFHC) diet for 15 weeks beginning when mice were eight weeks old. Adiposity 
measured by DEXA scan. (b,g) Adipose-specific IDOL KO mice (n=13 Idolf/f, n=17 
Idolf/fCreAdipoQ) fed a western diet for 15 weeks starting when the mice were six weeks old. 
Adiposity measured by MRI. (c,h) Endothelium-specific IDOL KO mice (n=21 Idolf/f, n=22 
Idolf/f CreCdh5) fed a western diet for 15 weeks starting when the mice were six weeks old. 
Adiposity measured by MRI. (d,i) Intestine-specific IDOL KO mice (n=13 Idolf/f, n=19 
Idolf/f CreVil) fed a western diet for 15 weeks starting when the mice were six weeks old. 
Adiposity measured by MRI. (e,j) Muscle-specific IDOL KO mice (n=11 Idolf/f, n=18 Idolf/f 
CreMck) fed a western diet for 15 weeks starting when the mice were six weeks old. 
Adiposity measured by MRI. There were no statistically significant differences between 
groups in any panel of this figure. The precise n-number, p-value, and details of the 
statistical testing are listed in the source data file.
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Figure 3: IDOL regulates systemic energy balance through the VLDL receptor.
(a) Growth curves showing the mean mass and the standard error of the mean (SEM) for 
male mice placed on a high fat high cholesterol (HFHC) diet from 6–8 weeks of age; n=11 
wild type (WT), n=18 Idol−/− (KO), n=18 Idol−/−Ldlr−/− (LDLR DKO) mice. (b) Growth 
curves showing the mean mass +/− SEM for male wild-type (WT) n=20, Idol−/− (IDOL KO) 
n=15, Vldlr−/− (VLDLR KO) n=12, and Idol−/−Vldlr−/− (VLDLR DKO) n=7 mice fed a 
HFHC diet from 6–8 weeks of age. (c) Intraperitoneal glucose tolerance test (1 g/kg) 
administered after six weeks on the HFHC diet. The values shown are the mean blood 
glucose levels +/− SEM. (d) Intraperitoneal insulin tolerance test (1U/kg) administered after 
ten weeks on the HFHC diet. The values shown are the mean blood glucose levels +/− SEM. 
(e) Adiposity reported as body fat percentage +/− SEM measured by MRI for the mice 
reported in panel (a) at baseline and after 8 weeks on the HFHC diet. (f) Adiposity reported 
as body fat percentage +/− SEM measured by MRI for the mice reported in panel (b) at 
baseline and after 8 weeks on the HFHC diet. (g) The area under the curve (AUC) was 
calculated for the glucose tolerance test for each mouse and the mean values +/− SEM and 
individual values are plotted. (h) The area under the curve (AUC) was calculated for the 
insulin tolerance test for each mouse and the mean values +/− SEM and individual values are 
plotted. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. The precise n-number, p-value, and 
details of the statistical testing are provided in the source data file.
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Figure 4: Acute knockdown of IDOL in the central nervous system reduces adiposity by 
increasing energy expenditure.
(a) Intracerebroventricular injection of a CNS-optimized antisense oligonucleotide (ASO) 
targeting Idol reduced Idol expression by 65% in the hypothalamus measured at study 
termination. The mean Idol expression +/− the standard error of the mean (SEM) is shown, 
p<0.0001 by two-tailed t-test n=8. (b) Growth curve showing the mean mass +/− SEM for 
male mice placed on western diet one week after ICV injection of Idol-targeting ASO or 
vehicle control (VEH); **p<0.01 by repeat measures ANOVA, n=10. (c) Increased VLDLR 
protein levels in the hypothalamus of IDOL KO mice 8 weeks after the ASO injection, the 
blots are representative of two independent analyses. (d) Adiposity reported as body fat 
percentage +/− SEM measured by MRI; n=10, ****p<0.0001 by repeat measures ANOVA 
(e) Hematoxylin and eosin stained subcutaneous white adipose tissue (sWAT) and 
interscapular brown adipose tissue (BAT) sections from mice after seven weeks of western 
diet feeding. (20x objective lens for sWAT and 40x objective lens for BAT, these images are 
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representative of five independent biological replicates) (f) Energy expenditure measured by 
indirect calorimetry in mice after 2–3 weeks on western diet showing the mean value per 
hour and +/− SEM; n=10 *p<0.05 VEH vs. ASO by ANCOVA using either total body mass 
or lean body mass as covariates. (g) Locomotor activity as measured when a mouse crossed 
multiple IR beams during the calorimetry experiment; mean values +/− SEM are shown for 
n=10 mice. (h) No difference in the overall locomotion of mice as quantified by the 
cumulative number of beam breaks in a 48-hour period +/− SEM; p=0.4772 by two-tailed t-
test; n=10. (i) Western blot analysis of the phosphorylation of hormone sensitive lipase 
(HSL) in subcutaneous white adipose tissue. This blot is representative of two independent 
analyses (j) Western blot analysis of tyrosine hydroxylase (TH) abundance in the brown 
adipose tissue. This blot is representative of two independent analyses. The precise n-
number, p-value, and details of the statistical testing are provided in the source data file.
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Figure 5: The single cell transcriptional landscape of the hypothalamus is affected by deletion of 
IDOL.
(a) Simplified schematic of the single cell RNA-sequencing experimental design. 5-week 
old mice were placed on a high fat, high cholesterol diet for two weeks. Hypothalamic 
tissues from six mice (n=3/group) were dissected and dissociated into single-cell suspension. 
Single cells and barcoded beads were captured into droplets followed by cDNA synthesis, 
amplification, and library preparation. The library was sequenced with an Illumina HiSeq 
4000 next-generation instrument using the Drop-seq custom read 1B primer. (b) Global gene 
expression relationships in the 11,453 single cells projected onto two dimensions using t-
distributed Stochastic Neighbor Embedding (tSNE). The clusters were defined using shared 
nearest neighbor graph-based clustering. (c) tSNE plot demonstrating the effect of IDOL 
knockout on the clustering of single cells in fifteen different neuron clusters; n=11,453 cells. 
(d) Volcano plot of the differentially expressed genes in AGRP neurons; expression data 
calculated as counts per 10k unique molecular identities (UMI); the p-values were calculated 
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using a two-tailed Wilcoxon rank sum tests from n=56 WT and n=45 Idol−/− neurons 
identified within the AGRP cluster. Labeled genes are linked to whole-body metabolic 
homeostasis – see Extended Data Table 1 for details). (e) Violin plots demonstrating that 
IDOL deletion reduced gene expression of Agrp and Npy in AGRP neurons. Individual data 
points indicate the magnitude of gene expression in a single cell. These are superimposed on 
a probability density plot for the distribution of the data; statistics were calculated using two-
tailed Wilcoxon rank sum tests on non-Ln transformed data; n=56 WT and n=45 IDOL KO 
neurons identified within the AGRP cluster.
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Figure 6: Conditional deletion of Idol from neurons drives the metabolic protection seen in 
global IDOL KO mice.
(a) Growth curve showing the mean mass +/− SEM and (b) Adiposity reported as body fat 
percentage +/− SEM measured by MRI for three cohorts of neuron-specific IDOL 
conditional knockout mice fed a western diet starting at 5–6 weeks old; n=18 per genotype 
*p<0.05, **p<0.01, ***p<0.001 ****p<0.0001 Idolf/f vs. Idolf/f CreSynI mice by repeat 
measures ANOVA. (c) Neuron-specific deletion of IDOL reduces food intake. The mean 
cumulative food consumption is shown +/− SEM; n=7 per genotype *p<0.05, ***p<0.001 
Idolf/f vs. Idolf/f CreSynI mice by repeat measures ANOVA. (d) Increased phosphorylation of 
hormone sensitive lipase in the subcutaneous white adipose tissue of neuron-specific 
conditional IDOL KO mice. Each lane was loaded with a protein lysate from independent 
mice. This blot is representative of two independent repeats. (e,f) Global IDOL KO mice are 
protected from diet-induced mass gain and adiposity when group-housed at 
thermoneutrality; n=6 WT, n=8 IDOL KO mice (e) Growth curve showing the mean mass 
gained +/− SEM. (f) Adiposity reported as body fat percentage +/− SEM measured by MRI 
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for adiposity. *p<0.05, ***p<0.001, ****p<0.0001 WT vs. KO by repeat-measures 
ANOVA. The precise n-number, p-value, and details of the statistical testing are provided in 
the source data file.
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